Tesamorelin 5mg

Tesamorelin Overview

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), developed to stimulate the body’s natural production of human growth hormone (HGH). Initially approved by the FDA for treating HIV-associated lipodystrophy, Tesamorelin has also gained attention for its potential applications in fat loss, metabolic regulation, and body composition improvement—though off-label uses should be approached with caution and under medical supervision.

1. Composition of the Peptide

• Tesamorelin is a synthetic peptide composed of the first 44 amino acids of human growth hormone-releasing hormone (GHRH).

• It is conjugated to a trans-3-hexenoic acid group to improve its stability and resistance to enzymatic degradation, allowing for better bioavailability and a longer half-life compared to native GHRH.

2. Benefits

Tesamorelin’s benefits are primarily linked to its ability to stimulate endogenous HGH release. Documented and potential benefits include:

• Reduction in visceral adipose tissue (VAT):

  • Clinically proven to reduce deep abdominal fat in HIV-positive patients with lipodystrophy.

  • VAT reduction observed without significant loss of subcutaneous fat.

• Improved lipid profile:

  • May reduce triglyceride levels and improve cholesterol ratios.

• Enhanced insulin-like growth factor 1 (IGF-1) levels:

  • Promotes anabolic processes, tissue repair, and cellular regeneration.

• Potential cognitive and neuroprotective benefits:

  • Early studies suggest Tesamorelin may positively influence cognitive function in older adults by modulating IGF-1.

• Body composition improvements (off-label observations):

  • Increased lean muscle mass.

  • Improved metabolic rate and fat oxidation.

  • May support better sleep and recovery via improved HGH secretion.

3. Sample Cycle or Dosage Protocol

📌 Important: The following protocol is based on clinical dosing guidelines and research settings. It is not a substitute for professional medical advice.

• Clinical Dose:

  • 2 mg subcutaneously (SQ) once daily, usually administered in the abdominal area.

  • Administered at bedtime to mimic natural circadian HGH release and optimize pituitary stimulation.

• Cycle Duration:

  • Clinical studies often span 12–26 weeks.

  • Visible reductions in visceral fat may begin within 2–3 months.